Company details
About
Steadfast and tenacious in our search for transformative therapies TARA-002 TARA-002 is the Company’s lead investigational cell therapy based on the broad immunopotentiator OK-432, which is approved in Japan and Taiwan for lymphatic malformations and multiple oncologic indications
Number of employees
1 - 10
Main industry
Biotechnology
Industry tags
Founded in
2017
Headquarters
New York
Country
United States
Sign up to uncover company details
5 free credit every month
Employee contacts
Name
Job Title
Phone
Reach Decision Makers
at Artara Therapeutics
